Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Genzyme Corporation
Woman and Man Max 99 years
Genzyme Corporation
Update Il y a 4 ans
A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy
The main objectives of study CAMMS32400507 is to compare the safety and efficacy of 2 annual cycles of 12 mg/day intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta-1a (Re...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genzyme Corporation
Update Il y a 4 ans
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT Estudio para evaluar la eficacia, la seguridad y la tolerabilidad de alemtuzumab en pacientes pediátricos con esclerosis múltiple recurrente remitente (EMRR) con actividad de la enfermedad en la terapia previa modificadora de la enfermedad (TME)
To evaluate the efficacy, safety, and tolerability of alemtuzumab (IV) in pediatric patients from 10 to <18 years of age with RRMS who have disease activity on prior DMT. Evaluar la eficacia, se...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3